Biotech | August 10, 2021
Eagle Pharmaceuticals announces licensing agreement for Landiolol
Deal signed with AOP Orphan for US commercial rights
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The drug is indicated for mild and transient episodes of heart block
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Filing for WHO Emergency Use Authorisation this month
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Board approves fundraise of Rs 1500 crore
Subscribe To Our Newsletter & Stay Updated
